Advertisement

Activity of macrolides against mycobacteria

  • Lowell S. Young
  • Luiz E. Bermudez
Chapter
  • 488 Downloads
Part of the Milestones in Drug Therapy MDT book series (MDT)

Abstract

The description of human disease caused by mycobacterial pathogens dates back to Biblical times. Presently, mycobacterial diseases account for a large proportion of all serious infectious disorders observed worldwide. Estimates of the numbers of leprosy cases exceed 20 million. Tuberculosis in all of its forms is believed to be the most common of the fatal infections, with total annual mortality figures of three million adult deaths of adults in developing countries (malaria may be numerically even more common but kills fewer patients) [1]. Tuberculosis is a re-emergent problem in many industrialized countries. In the modern world of global interdependency, rapid transportation, expanding trade, and migration, tuberculosis in any country is a threat to people of every country. The current global reemergence of tuberculosis can be attributed to several factors, among them, the HIVepidemic, social dislocation, poverty, overcrowding, and inadequate investment in public-health measures.

Keywords

Antimicrob Agent Mycobacterium Avium Mycobacterium Avium Complex Lepromatous Leprosy Beige Mouse 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Reference

  1. 1.
    Snider DE, Raviglione M, Kochi A (1994) Global burden of tuberculosis. In: B Bloom (ed): Tuberculosis Pathogenesis: Protection and Control. American Society for Microbiology, Washington, D.C., 3–12Google Scholar
  2. 2.
    Wolinsky E (1979) Nontuberculous mycobacteria and associated diseases. Am Rev Respir Dis 119:107–159PubMedGoogle Scholar
  3. 3.
    Falkinham JO, 3rd (1996) Epidemiology of infection by nontuberculous mycobacteria. Clin Microbiol Rev 9:177–215PubMedGoogle Scholar
  4. 4.
    Korvick JA, Benson CA (eds) (1996) Mycobacterium avium-complex infection. Progress in research and treatment. Marcel Dekker, Inc., New YorkGoogle Scholar
  5. 5.
    Runyon E (1959) Anonymous mycobacteria in pulmonary disease. Med Clin North Am 43: 273–290PubMedGoogle Scholar
  6. 6.
    Wallace RJ, Glassroth J, Griffith DE, Oliver KN, Cook JL, Gordon F (1997) Diagnostic and treatment of disease caused by non tuberculous mycobacteria. Am J Respir Crit Care Med 156(2): S 1-S25Google Scholar
  7. 7.
    Luna-Herrera J, Reddy VM, Daneluzzi D, Gangadharam PR. (1995) Antituberculosis activity of clarithromycin. Antimicrob Agents Chemother 39: 2692–2695PubMedCrossRefGoogle Scholar
  8. 8.
    Cavalieri SJ, Biehle JR, Sanders WE, Jr. (1995) Synergistic activities of clarithromycin and antituberculous drugs against multidrug-resistant Mycobacterium tuberculosis. Antimicrob Agents Chemother 39:1542–1545CrossRefGoogle Scholar
  9. 9.
    Truffot-Pernot C, Lounis N, Grosset JH, Ji B. (1995) Clarithromycin is inactive against Mycobacterium tuberculosis. Antimicrob Agents Chemother 39: 2827–2878PubMedCrossRefGoogle Scholar
  10. 10.
    Franzblau SG, Hastings RC. (1988) In vitro and in vivo activities of macrolides against Mycobacterium leprae. Antimicrob Agents Chemother 32:1758–1762CrossRefGoogle Scholar
  11. 11.
    Gelber RH (1990) Progress in the chemotherapy of leprosy: status, issues and prospects. Prog Drug Res 34: 421–445PubMedGoogle Scholar
  12. 12.
    Chan GP, Garcia-Ignacio BY, Chavez VE, Livelo JB, Jimenez CL, Parrilla ML, Franzblau SG. (1994) Clinical trial of clarithromycin for lepromatous leprosy. Antimicrob Agents Chemother 38: 515–517PubMedCrossRefGoogle Scholar
  13. 13.
    Ji B, Perani EG, Grosset JH (1991) Effectiveness of clarithromycin and minocycline alone and in combination against experimental Mycobacterium leprae infection in mice. Antimicrob Agents Chemother 35: 579–581PubMedCrossRefGoogle Scholar
  14. 14.
    Ji B, Jamet P, Perani EG, Bobin P, Grosset JH (1993) Powerful bactericidal activities of clarithromycin and minocycline against Mycobacterium leprae in lepromatous leprosy. J Infect Dis 168:188–190PubMedCrossRefGoogle Scholar
  15. 15.
    Casal M, Rodriguez F, Villalba R (1987) In vitro susceptibility of Mycobacterium avium to a new macrolide (RU- 28965). Chemotherapy 33: 255–258PubMedCrossRefGoogle Scholar
  16. 16.
    Bermudez LE, Young LS (1988) Activities of amikacin, roxithromycin, and azithromycin alone or in combination with tumor necrosis factor against Mycobacterium avium complex. Antimicrob Agents Chemother 32:1149–1153PubMedCrossRefGoogle Scholar
  17. 17.
    Prince DS, Peterson DD, Steiner RM et al. (1989) Infection with Mycobacterium avium complex in patients without predisposing conditions. N Engl J Med 321: 863–868PubMedCrossRefGoogle Scholar
  18. 18.
    Reich JM, Johnson RE (1992) Mycobacterium avium complex pulmonary disease presenting as an isolated lingular or middle lobe pattern. The Lady Windermere syndrome. Chest 101:1605–1609CrossRefGoogle Scholar
  19. 19.
    Inderlied CB, Nash KA (1996) Microbiology and in vitro susceptibility testing. In: JA Korvick, CA Benson (eds): Mycobacterium avium-complex infection: Progress in research and treatment. Marcel Dekker, Inc., New York, 109–140Google Scholar
  20. 20.
    Inderlied CB (1997) Microbiology and minimum inhibitory concentration testing for Mycobacterium avium complex prophylaxis. Am J Med 102: 2–10CrossRefGoogle Scholar
  21. 21.
    Ives DV, Davis RB, Currier JS (1995) Impact of clarithromycin and azithromycin on patterns of treatment and survival among AIDS patients with disseminated Mycobacterium avium complex. Aids 9: 261–266PubMedGoogle Scholar
  22. 22.
    Gangadharam PR, Edwards CK, 3rd, Murthy PS, Pratt PF (1983) An acute infection model for Mycobacterium intracellulare disease using beige mice: preliminary results. Am Rev Respir Dis 127: 648–649PubMedGoogle Scholar
  23. 23.
    Bertram MA, Inderlied CB, Yadegar S, Kolonoski P, Yamada JK, Young LS (1986) Confirmation of the beige mouse model for study of disseminated infection with Mycobacterium avium complex [letter]. J Infect Dis 154:194–195PubMedCrossRefGoogle Scholar
  24. 24.
    Young LS, Bermudez LE (1996) Animal models in anti-Mycobacterium avium-complex drug development. In: JA Korvick, CA Benson (eds) Mycobacterium avium complex infection: Progress in research and treatment. Marcel Dekker, Inc., New York, 141–161Google Scholar
  25. 25.
    Fernandes PB, Hardy DJ, McDaniel D, Hanson CW, Swanson RN (1989) In vitro and in vivo activities of clarithromycin against Mycobacterium avium. Antimicrob Agents Chemother 33: 1531–1534PubMedCrossRefGoogle Scholar
  26. 26.
    Inderlied CB, Kolonoski PT, Wu M, Young LS (1989) In vitro and in vivo activity of azithromycin (CP 62,993) against the Mycobacterium avium complex. J Infect Dis 159: 994–997PubMedCrossRefGoogle Scholar
  27. 27.
    Dautzenberg B, Truffot C, Legris S, Meyohas MC, Berlie HC, Mercat A, Chevret S, Grosset J (1991) Activity of clarithromycin against Mycobacterium avium infection in patients with the acquired immune deficiency syndrome. Am Rev Respir Dis 144: 561–569CrossRefGoogle Scholar
  28. 28.
    Young LS, Wiviott L, Wu M, Kolonoski P, Bolan R, Inderlied CB (1991) Azithromycin for treatment of Mycobacterium avium-intracellulare complex infection in patients with AIDS. Lancet 338: 1107–1109PubMedCrossRefGoogle Scholar
  29. 29.
    Chaisson RE, Benson CA, Dube MP, Heifets LB, Korvick JA, Elkin S, Smith T, Craft JC, Sattler FR (1994) Clarithromycin therapy for bacteremic Mycobacterium avium complex disease. A randomized, double-blind, dose-ranging study in patients with AIDS. AIDS Clinical Trials Group Protocol 157 Study Team. Ann Intern Med 121: 905–911PubMedGoogle Scholar
  30. 30.
    Koletar SL (1997) Treatment of Mycobacterium avium in human immunodeficiency virus-infected individuals. Am J Med 102: 16–21CrossRefGoogle Scholar
  31. 31.
    Struillou L, Cohen Y, Lounis N, Bertrand G, Grosset J, Vilde JL, Pocidalo JJ, Perronne C (1995) Activities of roxithromycin against Mycobacterium avium infections in human macrophages and C57BL/6 mice. Antimicrob Agents Chemother 39: 878–881PubMedCrossRefGoogle Scholar
  32. 32.
    Killian AD, Kanyok TP, Drusano GL (1996) Pharmacokinetics of drugs used for the therapy of Mycobacterim avium-complex infection. In: JA Korvick, CA Benson (eds) Mycobacterium avium-complex infection: Progress in research and treatment. Marcel Dekker, Inc., New York, 197–240Google Scholar
  33. 33.
    Gladue RP, Bright GM, Isaacson R., Newborg MF (1989) In vitro and in vivo uptake of azithromycin (CP-62,993) by phagocytic cells: possible mechanism of delivery and release at sites of infection. Antimicrob Agents Chemother 33: 277–282PubMedCrossRefGoogle Scholar
  34. 34.
    Ellis LC, Benson CA. Koenig GI., Trenholme GM (1995) Postantibiotic effect of clarithromycin alone and combined with ethambutol against Mycobacterium avium complex. Antimicrob Agents Chemother 39: 2803–2806PubMedCrossRefGoogle Scholar
  35. 35.
    Havlir DV, Dube MP, Sattler FR, Forthal DN, Kemper CA, Dunne MW, Parenti DM, Lavelle JP, White AC, Jr., Witt MD et al (1996) Prophylaxis against disseminated Mycobacterium avium complex with weekly azithromycin, daily rifabutin, or both. California Collaborative Treatment Group. N Engl J Med 335: 392–398PubMedCrossRefGoogle Scholar
  36. 36.
    Benson CA, Williams PL, Cohn DL, Becker S, Hojczyk P, Nevin T, Korvick JA, Heifets L, Child CC, Lederman MM et al (2000) Clarithromycin or rifabutin alone or in combination for primary prophylaxis of Mycobacterium avium complex disease in patients with AIDS: A randomized, double-blind, placebo-controlled trial. The AIDS Clinical Trials Group 196/Terry Beim Community Programs for Clinical Research on AIDS 009 Protocol Team. J Infect Dis 181: 1289–1297PubMedCrossRefGoogle Scholar
  37. 37.
    Wallace RJ Jr., Brown BA, Griffith DE, Girard WM, Murphy DT, Onyi GO, Steingrube VA, Mazurek GH (1994) Initial clarithromycin monotherapy for Mycobacterium avium-intracellulare complex lung disease. Am J Respir Crit Care Med 149: 1335–1341PubMedGoogle Scholar
  38. 38.
    Wallace RJ Jr. (1994) Recent changes in taxonomy and disease manifestations of the rapidly growing mycobacteria. Eur J Clin Microbiol Infect Dis 13: 953–960PubMedCrossRefGoogle Scholar
  39. 39.
    Brown BA, Wallace RI Jr., Onyi GO (1992) Activities of clarithromycin against eight slowly growing species of nontuberculous mycobacteria, determined by using a broth microdilution MIC system. Antimicrob Agents Chemother 36: 1987–1990PubMedCrossRefGoogle Scholar
  40. 40.
    Wallace RJ Jr., Tanner D, Brennan PJ, Brown BA (1993) Clinical trial of clarithromycin for cutaneous (disseminated) infection due to Mycobacterium chelonae. Ann Intern Med 119: 482–486Google Scholar
  41. 41.
    Carbonara S, Tortoli E, Costa D, Monno L, Fiorentino G, Grimaldi A, Boscia D, Rollo MA, Pastore G, Angarano G (2000) Disseminated Mycobacterium terrae infection in a patient with advanced human immunodeficiency virus disease. Clin Infect Dis 30: 831–835PubMedCrossRefGoogle Scholar
  42. 42.
    Sanders JW, Walsh AD, Snider RL, Sahn EE (1995) Disseminated Mycobacterium scrofulaceum infection: a potentially treatable complication of AIDS. Clin Infect Dis 20: 549PubMedCrossRefGoogle Scholar
  43. 43.
    Portaels F, Traore H, De Ridder K, Meyers WM (1998) In vitro susceptibility of Mycobacterium ulcerans to clarithromycin. Antimicrob Agents Chemother 42: 2070–2073PubMedGoogle Scholar
  44. 44.
    Matsiota-Bernard P, Thierry D, De Truchis P, Saillour M, Paraire F, Guesdon JL, Nauciel C (1995) Mycobacterium genovense infection in a patient with AIDS who was successfully treated with clarithromycin. Clin Infect Dis 20:1565–1566PubMedCrossRefGoogle Scholar
  45. 45.
    Kiehn TE, White M (1994) Mycobacterium haemophilum: an emerging pathogen. Eur J Clin Microbiol Infect Dis 13: 925–931PubMedCrossRefGoogle Scholar
  46. 46.
    Buchholz UT, McNeil MM, Keyes LE, Good RC (1998) Mycobacterium malmoense infections in the United States, January 1993 through June 1995. Clin Infect Dis 27: 551–558PubMedCrossRefGoogle Scholar
  47. 47.
    Mushatt DM, Witzig RS (1995) Successful treatment of Mycobacterium abscessus infections with multidrug regimens containing clarithromycin. Clin Infect Dis 20:1441–1442PubMedCrossRefGoogle Scholar
  48. 48.
    Roberts MC, Sutcliffe J, Courvalin P, Jensen LB, Rood J, Seppala H (1999) Nomenclature for macrolide and macrolide-lincosamide-streptogramin B resistance determinants. Antimicrob Agents Chemother 43: 2823–2830Google Scholar
  49. 49.
    Doucet-Populaire F, Truffot-Pernot C, Grosset J, Jarlier V (1995) Acquired resistance in Mycobacterium avium complex strains isolated from AIDS patients and beige mice during treatment with clarithromycin. J Antimicrob Chemother 36: 129–136PubMedCrossRefGoogle Scholar
  50. 50.
    Nash KA, Inderlied CB (1996) Rapid detection of mutations associated with macrolide resistance in Mycobacterium avium complex. Antimicrob Agents Chemother 40: 1748–1750PubMedGoogle Scholar
  51. 51.
    Bermudez LE, Petrofsky M, Kolonoski P, Young LS (1998) Emergence of Mycobacterium avium populations resistant to macrolides during experimental chemotherapy. Antimicrob Agents Chemother 42: 180–183PubMedGoogle Scholar
  52. 52.
    Bermudez LE, Inderlied CB, Kolonoski P, Petrofsky M, Young LS (1994) Clarithromycin, dapsone, and a combination of both used to treat or prevent disseminated Mycobacterium avium infection in beige mice. Antimicrob Agents Chemother 38: 2717–2721PubMedCrossRefGoogle Scholar
  53. 53.
    Griffith DE, Wallace RJ (1997) Treatment of pulmonary Mycobacterium avium complex lung disease in non-acquired immunodeficiency syndrome (AIDS) patients in the era of the newer macrolides and rifabutin. Am J Med 102: 22–27CrossRefGoogle Scholar
  54. 54.
    Shafran SD, Singer J, Zarowny DP, Phillips P, Salit I, Walmsley SL, Fong IW, Gill MJ, Rachlis AR, Lalonde RG, Fanning MM, Tsoukas CM (1996) A comparison of two regimens for the treatment of Mycobacterium avium complex bacteremia in AIDS: rifabutin, ethambutol, and clarithromycin versus rifampin, ethambutol, clofazimine, and ciprofloxacin. Canadian HIV Trials Network Protocol 010 Study Group. N Engl J Med 335: 377–383PubMedCrossRefGoogle Scholar
  55. 55.
    Bermudez LE, Inderlied CB, Kolonoski P et al. (1998) Activity of HMR3004 against Mycobacterium avium complex in vitro, in human macrophages and in beige mice. Clin Microb Infect 4: 325–331CrossRefGoogle Scholar
  56. 56.
    Bermudez LE, Inderlied CB, Kolonoski P, Wu M, Aralar P, Young LS (2001) Telithromycin is active against Mycobacterim avium in mice despite lacking significant activity in standard in vitro and macrophage assays and is associated to low frequency of resistance during treatment Antimicrob Agents Chemother 45: 2210–2216PubMedCrossRefGoogle Scholar
  57. 57.
    Cynamon MH, Carter JL, Shoen CM (2000) Activity of ABT-773 against Mycobacterium avium complex in the beige mouse model. Antimicrob Agents Chemother 44: 2895–2896PubMedCrossRefGoogle Scholar

Copyright information

© Springer Basel AG 2002

Authors and Affiliations

  • Lowell S. Young
    • 1
  • Luiz E. Bermudez
    • 1
  1. 1.Kuzell Institute for Arthritis and Infectious DiseasesCalifornia Pacific Medical Center Research InstituteSan FranciscoUSA

Personalised recommendations